linjc16/ctgov huggingface dataset:
The Association Between Uterine Artery Notch and First Trimester Bleeding

Study Overview
=================
Brief Summary
-----------------
The purpose of the present study is to evaluate the occurrence of first trimester bleeding among patients with abnormal uterine artery Doppler. A prospective study is designed and two groups will be studied; patients with abnormal uterine artery Doppler at second trimester (study group) and patient with normal uterine artery Doppler at second trimester (control group).The patients will be asked, as part of the routine history taken before the US about having first trimester bleeding during the current pregnancy.

Detailed Description
-----------------
The purpose of the present study is to evaluate the occurrence of first trimester bleeding among patients with abnormal uterine artery Doppler. A prospective study is designed and two groups will be studied; patients with abnormal uterine artery Doppler at second trimester (study group) and patient with normal uterine artery Doppler at second trimester (control group). Both the study group and the control group represent high risk pregnant patients and the Doppler flows are done as part of the patient's predictive risk for placental associated abnormalities. The patients will be asked, as part of the routine history taken before the US about having first trimester bleeding during the current pregnancy.

Official Title
-----------------
The Association Between Uterine Artery Notch and First Trimester Bleeding

Conditions
-----------------
Uterine Artery Notch, First Trimester Bleeding

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with abnormal uterine artery Doppler at second trimester Exclusion Criteria: Multi fetal pregnancies Patients without known gestational age (according to last month period or first trimester ultrasound Pregnancies with congenital structural or chromosomal anomalies Lack of prenatal care
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| presence of uterine artery notch<br>patients with uterine artery notch during the 2nd and 3rd trimester | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
notch, uterine, first, bleeding
A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.

Study Overview
=================
Brief Summary
-----------------
This single arm study will evaluate the efficacy and safety of sequential treatment with Diavobet (betamethasone propionate 0.5mg/g plus calcipotriol hydrate 50 micrograms/g) once daily for 4 weeks followed by Daivonex (calcipotriol hydrate 50 micrograms/g) twice daily for 4 weeks, in the control of signs and symptoms in patients with mild to moderate psoriasis. Only patients showing a >50% response to Daivobet will progress to the Daivonex maintenance phase. The anticipated time on study treatment is <3 months, and the target sample size is 100-500 individuals.

Official Title
-----------------
An Open Label Study to Evaluate the Clinical Response to Sequential Treatment With Daivobet and Daivonex in Patients With Mild to Moderate Psoriasis

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Drug: calcipotriol hydrate [Daivonex]


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients >=18 years of age; clinical diagnosis of psoriasis vulgaris; PASI score 1-12 in >=1 body area. Exclusion Criteria: clinical presentation of erythrodermic pustular psoriasis, expressed in plates and localized lesions on face and/or scalp; viral, fungal or bacterial skin infections; use of any topical treatment for psoriasis within previous 15 days; use of any systemic therapy and phototherapy for psoriasis within previous 30 days.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: calcipotriol hydrate [Daivonex]<br>* 50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a >50% response to Daivobet from weeks 0-4.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PASI reduction |  | Weeks 4 and 8 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AEs. |  | Throughout study |
A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if valganciclovir is a safe treatment for CMV retinitis in patients who have been treated for this condition in the past. This study also examines the effectiveness of valganciclovir in preventing the recurrence of CMV retinitis.

Detailed Description
-----------------
Patients receive valganciclovir twice a day for 21 days as induction therapy then daily as maintenance therapy. Patients are encouraged to remain on study for at least 3 months and will remain until common study closure.

Official Title
-----------------
An Open Label Study of the Safety and Tolerability of Valganciclovir, an Oral Prodrug of Ganciclovir, for the Treatment of Cytomegalovirus Retinitis in Subjects With AIDS

Conditions
-----------------
Cytomegalovirus Retinitis, HIV Infections

Intervention / Treatment
-----------------
* Drug: Valganciclovir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Concurrent Medication: Allowed with caution: Acyclovir. Famciclovir. Valaciclovir. Imipenem-cilastatin. Myelosuppressive agents. Patients must have: HIV infection with CMV retinitis. Minimum of 4 weeks prior treatment with ganciclovir, foscarnet, or cidofovir. Intraocular implant in either or both eyes, as long as CMV retinitis is active in one eye, upon approval by Roche. Exclusion Criteria Co-existing Condition: Patients with any of the following symptoms of conditions are excluded: Active extraocular CMV disease. Severe uncontrolled diarrhea or evidence of malabsorption. Concurrent Medication: Excluded: Foscarnet. Cidofovir. CMV hyperimmune globulin. Probenecid. Patients with the following prior conditions are excluded: Ocular media opacities (corneal, aqueous, lens, or vitreous) preventing ophthalmologic retinal assessment. Simultaneous participation in another study (unless approved by Roche). Required: A minimum of 4 weeks treatment with ganciclovir, foscarnet, or cidofovir. Approval required for prior use of investigational anti-CMV agents.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Valganciclovir|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AIDS-Related Opportunistic Infections, Ganciclovir, Antiviral Agents, Drug Administration Schedule, Cytomegalovirus Retinitis, Prodrugs
Immune Repertoire of Ovarian HGSC

Study Overview
=================
Brief Summary
-----------------
In this preliminary study, peripheral blood and carcinoma tissue with pericarcinomatous tissue are taken from the patients with ovarian high grade serous carcinoma at several points: before any treatment, after the debulking surgery, and after all the proposed chemotherapy. The differential expression of the T/B lymphocyte receptors in these samples will be analyzed with the platinum-based treatment and survival outcomes of the patients. The primary objective is the expression rates of T/B lymphocyte receptors in different stages of checking points.

Official Title
-----------------
Differential Expression of Immune Repertoire of T/B Lymphocytes in Ovarian High Grade Serous Carcinoma

Conditions
-----------------
Ovarian High Grade Serous Carcinoma, Immune Repertoire, T Lymphocyte Receptor, B Lymphocyte Receptor

Intervention / Treatment
-----------------
* Procedure: Treatment for ovarian cancer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed of primary ovarian high grade serous carcinoma Aged 18 years or older No immunosuppressive disease Signed an approved informed consents Exclusion Criteria: Not meeting all of the inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Treatment for ovarian cancer|The treatment for ovarian cancer includes the debulking surgery and platinum-based chemotherapy.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Expression rates of T lymphocyte receptors | Expression rates of T lymphocyte receptors in different stages of checking points, including timings before any treatment, after the debulking surgery, and after all the proposed chemotherapy | One year | 
| Expression rates of B lymphocyte receptors | Expression rates of T lymphocyte receptors in different stages of checking points, including timings before any treatment, after the debulking surgery, and after all the proposed chemotherapy | One year |
Drug Interactions With Risk of QT-prolongation in a General Hospital

Study Overview
=================
Brief Summary
-----------------
In this epidemiological point prevalence study, medication profiles of patients with haloperidol treatment will be checked for drug interactions with risk of QT-prolongation. Additional clinical risk factors for developing QT-prolongation and safety measurements will be documented.

Detailed Description
-----------------
Study design: epidemiological point prevalence study Target population: Patients with haloperidol treatment The following aspects will be investigated: The medication profiles will be checked for drug interactions with risk of QT-prolongation. Clinical risk factors for developing QT-prolongation (gender, age, (history of) cardiovascular disease, comorbidity,...) and lab results will be collected. Safety measurements (e.g. ECG) will be documented.

Official Title
-----------------
Drug Interactions With Risk of QT-prolongation in a General Hospital: an Epidemiological Point Prevalence Study

Conditions
-----------------
QT-prolongation

Intervention / Treatment
-----------------
* Drug: Haloperidol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: treatment with haloperidol (started in the hospital) Exclusion Criteria: age < 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients treated with haloperidol<br> | Drug: Haloperidol<br> <br> * Other names: Haldol;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QTc-interval (corrected for heart rate) |  | maximum one year before inclusion / one week after inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of drug interactions (with risk of QT-prolongation) |  | one week before/after inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
QT-prolongation, Torsade de Pointes, Haloperidol, Drug interactions
Can we Rely on HLA to Predict Resistance to Biological Therapy in IBD Patients

Study Overview
=================
Brief Summary
-----------------
The investigators propose an observational study including patients with inflammatory bowel disease under biological therapy with anti-TNF, anti-integrin α₄β₇ or anti-interleukin 12-23 (Ustekinumab), followed by an external Gastroenterology consultation at Centro Hospitalar Tondela-Viseu.

Official Title
-----------------
Can we Rely on HLA to Predict Resistance to Biological Therapy in IBD Patients

Conditions
-----------------
Inflammatory Bowel Diseases

Intervention / Treatment
-----------------
* Genetic: HLA-DQA1*05 and DRB1


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with the diagnosis of IBD (according to ECCO diagnosis criteria); Adult patients (over 18 years); Full capability of signing informed consent. Exclusion Criteria: Patients who refuse to participate in the study; Patients submitted to prior biological therapy (only for the IBD-naive group)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy Subjects<br>Blood donors | Genetic: HLA-DQA1*05 and DRB1<br>* All patients will be asked to give blood samples to search for HLA-DQA1*05 and DRB1<br>|
| IBD patients - under biological therapy<br>Patients with IBD followed up in consultation on biological therapy with anti-TNF, anti-integrin α₄β₇ or anti-interleukin 12-23. | Genetic: HLA-DQA1*05 and DRB1<br>* All patients will be asked to give blood samples to search for HLA-DQA1*05 and DRB1<br>|
| IBD patients - naive<br>Patients newly diagnosed with IBD and need for biological therapy with anti-TNF, anti-integrin α₄β₇ or anti-interleukin 12-23, | Genetic: HLA-DQA1*05 and DRB1<br>* All patients will be asked to give blood samples to search for HLA-DQA1*05 and DRB1<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response to biological therapy | To assess whether the presence of the HLA-DQA1*05 and HLA DRB1 alleles in patients with inflammatory bowel disease is associated with primary failure or loss of response to biological therapy with anti-TNF (Infliximab and Adalimumab), anti-integrin α₄β₇ (Vedolizumab) or anti-interleukin 12-23 (Ustekinumab). | 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of HLA-DQ1*05 and DRB1 | To determine the prevalence of HLA-DQ1*05 and DRB1 alleles in IBD population and to compare with a population of healthy blood donor patients. | 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Inflammatory Bowel Diseases, HLA, Biological therapy
Drug Use During Sex and Its Impact on Taking PrEP (Pre-Exposure Prophylaxis) : CONSUME

Study Overview
=================
Brief Summary
-----------------
This is a cross-sectional, single-center observational study conducted from October 2020 to March 2021 in Ile de France at the infectious disease of CHU Bichat (PrEP and CeGIDD(Free Center for Information, Screening and Diagnosis of Infections by Human Immunodeficiency Viruses, Viral Hepatitis and Sexually Transmitted Infections) consultation). It concerns adult subjects of male or transgender sex, of MSM (men having sex with men) or bi-sexual orientation. The data are collected by self-questionnaire evaluating the consumption of Chemsex (drug use in a sexual context) over the last 12 months, the existence or not of addiction treatment, the history of STIs (sexually transmitted infections) and adherence to PrEP (for subjects taking PrEP) during the last sexual intercourse (ANRS questionnaire, used in the PREVENIR study).

Official Title
-----------------
The Use of Chemsex (Drug Use in a Sexual Context) Among MSM (Men Who Have Sex With Men) and Transgender People in France, Whether or Not Taking PrEP, and Its Impact on PrEP Adherence

Conditions
-----------------
Drug Dependence

Intervention / Treatment
-----------------
* Behavioral: self-questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age> 18 male or transgender MSM or bi-sexual orientation adult consultant at Bichat Hospital (CeGIDD or PrEP consultation) adult with a Smartphone (online self-questionnaire) Exclusion Criteria: For the group taking PrEP: adult taking PrEP for less than 3 months Refusal of participation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| male or transgender patients<br>of sexual orientation MSM (men having sex with men) or bi-sexual, consultant in sexual health centers | Behavioral: self-questionnaire<br>* self-questionnaire assessing Chemsex's (drug use in a sexual context) consumption over the last 12 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| compare in an MSM and transgender population, the use of Chemsex depending on whether or not PrEP is taken |  | inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reported adherence to PrEP |  | inclusion | 
| The existence or not of psychological comorbidity and the existence of addictological care |  | inclusion | 
| The number of sexually transmitted infections at inclusion |  | inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chemsex, PrEP
Prediction of Postoperative Pain by Injection Pain of Propofol

Study Overview
=================
Brief Summary
-----------------
Postoperative pain is a significant postoperative problem and it could be persistent if proper management is not provided. However, each patient shows different intensity of pain and different sensitivity to analgesics even if they underwent same procedures. Therefore, it would be useful to find the way to predict the postoperative pain sensitivity. Propofol, a popular anesthetic agent, induces pain during injection, which can not completely prevented by opioid or lidocaine in some patients. This is considered to be related to patient's pain sensitivity and it might be associated with postoperative pain sensitivity. Therefore, the relation of propofol injection pain and postoperative pain intensity will be explored.

Conditions
-----------------
Cholecystitis, Acute

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: America Society of Anesthesiologists class I-II Laparoscopic cholecystectomy Exclusion Criteria: Pregnancy Illiteracy

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative pain intensity_1 | Postoperative pain will be evaluated with verbal numeric scale (0-10) | 10 min after postanesthesia care unit admission | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative pain intensity_2 | Postoperative pain will be evaluated with verbal numeric scale (0-10) | 20 min after postanesthesia care unit admission | 
| postoperative pain intensity_3 | Postoperative pain will be evaluated with verbal numeric scale (0-10) | 30 min after postanesthesia care unit admission | 
| postoperative pain intensity_4 | Postoperative pain will be evaluated with verbal numeric scale (0-10) | 4 hours after operation | 
| postoperative pain intensity_8 | Postoperative pain will be evaluated with verbal numeric scale (0-10) | 8 hours after operation | 
| postoperative pain intensity_12 | Postoperative pain will be evaluated with verbal numeric scale (0-10) | 12 hours after operation | 
| postoperative pain intensity_24 | Postoperative pain will be evaluated with verbal numeric scale (0-10) | 24 hours after operation |